Analyzing the Key Fundamentals of Bath & Body Works (BBWI)

We're taking a closer look at Bath & Body Works today, as the chatter surrounding the stock has increased notably in the last few weeks. Today, its shares moved 2.4% compared to 1.0% for the S&P 500. Increased investor interest and volatility surrounding the stock are not reason enough to buy in -- you should first perform your own due diligence. Here are some figures that can get you started:

  • Bath & Body Works, Inc. operates a specialty retailer of home fragrance, body care, and soaps and sanitizer products.

  • Bath & Body Works has moved 30.5% over the last year compared to 23.5% for the S&P 500 -- a difference of 7.0%

  • BBWI has an average analyst rating of buy and is 0.72% away from its mean target price of $51.57 per share

  • Its trailing 12 month earnings per share (EPS) is $3.84

  • Bath & Body Works has a trailing 12 month Price to Earnings (P/E) ratio of 13.5 while the S&P 500 average is 27.65

  • Its forward earnings per share (EPS) is $3.76 and its forward P/E ratio is 13.8

  • BBWI has a Price to Earnings Growth (PEG) ratio of 3.05, which shows the company is potentially overvalued when we factor growth into the price to earnings calculus.

  • Bath & Body Works is part of the Consumer Cyclical sector, which has an average P/E ratio of 22.06 and an average P/B of 3.18

  • Bath & Body Works has on average reported free cash flows of $1.01 Billion over the last four years, during which time they have grown by an an average of -3.0%

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.